title: Intracisternally injected galanin-(1-15) modulates the cardiovascular responses of galanin-(1-29) and the 5-HT1A receptor agonist 8-OH-DPAT.
abstract: In view of the demonstration of specific binding sites for [125I]galanin-(1-15) in several brain areas including the nucleus of the solitary tract, possibly indicating the existence of multiple galanin receptor subtypes, the effects of intracisternal injections of galanin-(1-15) on cardiovascular parameters were studied. The effects of co-injections of galanin-(1-15) and galanin-(1-29) and co-injections of galanin-(1-15) and the 5-HT1A receptor agonist 8-OH-2-(di-n-propylamino)tetralin (8-OH-DPAT) were also evaluated. Galanin-(1-15) produced a significant increase in mean arterial blood pressure (maximum effect 10% at 3 nmol of galanin-(1-15)) and in heart rate (maximum effect 12% at 1 nmol). When threshold doses of galanin-(1-15) (0.1 nmol) and galanin-(1-29) (3 nmol) were injected simultaneously they elicited an increase in mean arterial blood pressure. The vasodepressor response induced by an ED50 dose of 8-OH-DPAT (6 nmol) was not modulated by a threshold dose of galanin-(1-15), but the increase in heart rate area induced by galanin-(1-15) alone was no longer observed. When threshold doses of both galanin-(1-15) and 8-OH-DPAT (0.3 nmol) were co-injected a vasodepressor response developed and on heart rate a tachycardic response was seen in the peak effects and the overall tachycardic response induced by galanin-(1-15) was sustained. The results show a different role for galanin-(1-15) as compared with galanin-(1-29) in central cardiovascular control.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Physiology, Faculty of Medicine, University of Málaga, Spain.
authors.forename: J A
authors.initials: JA
authors.lastname: Narváez
authors.forename: Z
authors.initials: Z
authors.lastname: Diaz
authors.forename: J A
authors.initials: JA
authors.lastname: Aguirre
authors.forename: S
authors.initials: S
authors.lastname: González-Barón
authors.forename: N
authors.initials: N
authors.lastname: Yanaihara
authors.forename: K
authors.initials: K
authors.lastname: Fuxe
authors.forename: P B
authors.initials: PB
authors.lastname: Hedlund
mesh_terms: D017371:8-Hydroxy-2-(di-n-propylamino)tetralin / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D002946:Cisterna Magna; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004357:Drug Synergism; D019004:Galanin; D006339:Heart Rate / Q000187:drug effects*; D008297:Male; D009479:Neuropeptides / Q000008:administration & dosage / Q000494:pharmacology; D010446:Peptide Fragments / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D010455:Peptides / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012119:Respiration / Q000187:drug effects
chemical_list: D009479:Neuropeptides; D010446:Peptide Fragments; D010455:Peptides; C086813:galanin (1-15); D017371:8-Hydroxy-2-(di-n-propylamino)tetralin; D019004:Galanin